Skip to Content


In the US, Gemtuzumab (gemtuzumab systemic) is a member of the drug class CD33 monoclonal antibodies and is used to treat Acute Myeloid Leukemia.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Therapeutic Categories

Cytostatic agent


Chemical Name

Immunoglobulin G4 (human-mouse monoclonal hP67.6 gamma 4-chain anti-human antigen CD 33), disulfide wit human-mouse monoclonal hP67.6 gamma-chain, dimer (WHO)

Foreign Names

  • Gemtuzumabum (Latin)
  • Gemtuzumab (German)
  • Gemtuzumab (French)
  • Gemtuzumab (Spanish)

Generic Names

Brand Names

  • Mylotarg
    Pfizer, France; Pfizer Japan, Japan


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.